Biotechnology company Surge Therapeutics raised $26 million in series A financing.
The company will use the funds to expand its immunotherapies designed to improve postsurgical outcomes for patients, according to an Oct. 17 news release from Surge. Additionally, the company will look to fund trials for its biodegradable hydrogel injected into the site of tumor resection.
The funding round was led by Camford Capital.
"Surge seeks to radically redefine the process of care for cancer patients, creating a simple and effective treatment that could potentially be administered during any surgical oncology procedure," Robert Langer, chair of Surge's scientific advisory board, said in the release. "Surge's novel approach has the potential to usher in a new pillar of cancer immunotherapy that could markedly enhance survival outcomes."